| heparan sulfate proteoglycans |
drug |
2 |
— |
|
| heparin |
drug |
9 |
3 |
|
| hepatic encephalopathy |
phenotype |
6 |
3 |
HE, Hepatic Encephalopathy, PSE, portal-systemic encephalopathy |
| hepatic steatosis |
phenotype |
8 |
6 |
benign steatosis, centrilobular steatosis, hepatic steatosis, liver steatosis |
| hepatitis |
phenotype |
3 |
1 |
|
| hepatocellular carcinoma |
phenotype |
9 |
3 |
HCC |
| HEPES |
drug |
16 |
4 |
HEPES, HEPES (pH 7.6), HEPES buffer, HEPES-based recording solution, N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid] |
| HEPES buffer |
drug |
2 |
2 |
HEPES |
| HepG2 |
cohort |
6 |
1 |
|
| heritability |
phenotype |
22 |
9 |
SNP-based heritability, estimated heritability, h2 |
| heroin self-administration |
phenotype |
3 |
— |
heroin SA |
| heroin users |
phenotype |
6 |
5 |
heroin consumption |
| HES1 |
gene |
2 |
2 |
Hairy and Enhancer of Split-1 |
| hESCs |
cohort |
4 |
2 |
human embryonic stem cells |
| HFD |
drug |
3 |
3 |
high-fat diet, high‑fat diet |
| hg19 |
drug |
8 |
5 |
GRCh37, human genome hg19, human reference genome hg19, reference human genome hg19 |
| HHIP |
gene |
4 |
2 |
|
| hidden Markov model |
drug |
4 |
3 |
HMM |
| High Capacity cDNA Reverse Transcription kit |
drug |
3 |
1 |
Applied Biosystems cDNA Reverse Transcription Kit |
| Higher socioeconomic status |
phenotype |
2 |
1 |
higher SES, higher SES attainment, higher socioeconomic status |
